CD274 and cancer: The discovery of immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1) and programmed cell death ligand 1 (PD-L1) has led to a dramatic paradigm shift for cancer treatment, and MSI-H/dMMR is vulnerable to ICIs due to high immunogenicity and heavy infiltration of immune cells.